Citigroup - Mylan "buy"

hier:
Frankfurt 17,352  € +1,97% 17,016 € 5 5 17,352 -  17,352 09:18:41
5 Stücke ;-)  

Frankfurt 17,47  € +0,10% 17,451 € 25 25 17,47 -  17,47 09:30:17

.                             ...*fg* ;o)  

US-amerikanischen Pharmaunternehmen. Kernkompetenz der Gesellschaft ist die Entwicklung, Herstellung und Vermarktung von Generika (Nachahmer-Medikamente, deren Patentschutz abgelaufen ist) und eigenen Marken-Pharmazeutika. Zudem werden aktive pharmazeutische Inhaltsstoffe (API) für die Pharmaindustrie angeboten. Zu den im Produktportfolio befindlichen Generika gehören solche gegen Herz-Kreislauf-Beschwerden (z.B. Clonidine Transdermal System), gegen Diabetes (z.B. Glipizide und Metformin Hydrochloride Tabletten) oder gegen vermindernden Harndrang (z.B. Spironolactone). Hier umfasst das Sortiment des Konzerns derzeit über 140 verschiedene Produkte. Mit seinen Tochtergesellschaften Merck Generics, Mylan Pharmaceuticals und UDL Laboratories werden in fast allen Therapiegebieten kostengünstige Standardtherapien durch qualitativ hochwertige generische Arzneimittel auf den Markt gebracht. Eine besondere Kompetenz hat das Unternehmen zudem bei der Verabreichung von Wirkstoffen über die Haut mittels spezieller Pflaster. Im Bereich der Markenprodukte bietet Mylan vor allem spezielle Aerosole und Injektoren an.  

14:10 08.06.12

PR Newswire

PITTSBURGH, June 8, 2012

PITTSBURGH, June 8, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has resolved all disputes with Teva Pharmaceuticals USA, Inc. stemming from litigation brought by Mylan in federal court in the District of Columbia against the U.S. Food and Drug Administration (FDA) concerning Mylan's abbreviated new drug application (ANDA) for Modafinil Tablets, 100 mg and 200 mg. Modafinil Tablets are the generic version of Cephalon's Provigil®, indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder.

Pursuant to the terms of the agreement with Teva, Mylan is permitted to launch its Modafinil Tablets, 100 mg and 200 mg, on August 10, 2012, which is prior to the expiration of the 180-day marketing exclusivity period granted to Teva. Other details of the settlement are confidential, and the agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Modafinil Tablets, 100 mg and 200 mg, had U.S. sales of $1.2 billion for the 12 months ending March 31, 2012, according to IMS Health.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement of the litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.
Quelle: PR Newswire  

letzter Stand/shares
  15.06.12     21,09     21,27§20,96 21,20 $ 4.596.225 96,6 M  

MfG B.

......(MEZ::Mittel Europäische Zeit)  

http://www.ariva.de/news/Mylan-Comments-on-Copaxone-Ruling-4149745  

committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
http://www.ariva.de/news/Mylan-Comments-on-Copaxone-Ruling-4149745  

so steht es auf der Briefseite,also wer Mylan-Anteile haben möchte bitte 24,00 $
sonne glatte Zahl rechnet sich für die meisten auch gut,genau als wenn sagen tut "stimmt so" also kinderleichte Handhabe bei Mylan heute.Ab 15:30Uhr wird bedient,die Orders können aber rund um die Uhr gestellt und geflankt werden.das nur eben noch mal kurz nebenbei,Gruss Buran  

http://www.ariva.de/news/...lenge-Relating-to-Pristiq-Tablets-4155477  

http://www.ariva.de/news/...-Thiamine-Hydrochloride-Injection-4155478  

enormer Drang in der Briefseite  

somit kommen wir auf Einundzwanzig - Abfahrt Altona ;-)  

saldo wird kasse gemacht  

Gruss Buran  

 

 

 

 

 

"Food and Drug Administration Safety and Innovation Act"

23:25 09.07.12

PR Newswire

PITTSBURGH, July 9, 2012

PITTSBURGH, July 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today applauded President Obama's signing of the "Food and Drug Administration Safety and Innovation Act," landmark legislation that will significantly enhance the safety and security of the U.S. drug supply chain, level the playing field to hold all drug manufacturers to FDA's inspection standards and improve timely access to high quality, affordable generic drugs.  

Mylan CEO Heather Bresch commented, "Mylan has long been a passionate leader and advocate for many of the key provisions included in this important piece of legislation that will help enhance our nation's drug supply chain, and we applaud the extraordinary efforts of the many in Congress who helped craft and pass this vital law in a bipartisan fashion. We believe these important updates to the 1938 law governing FDA will help to protect the health and safety of consumers by globalizing the reach of FDA to reflect today's global pharmaceutical supply chain and ensuring that all drug manufacturing facilities that supply the U.S. market are regularly inspected, regardless of whether they are based inside the U.S. or outside our borders. In particular, I am proud that the generics industry, through the landmark Generic Drug User Fee Act, has stepped up to the plate to help address an industry wide issue by providing FDA with approximately $1.5 billion over five years in order to help fund these increased inspections of drug facilities and ensure faster and more predictable review of generic drug applications."

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.
Quelle: PR Newswire  

http://www.ariva.de/news/...-Conference-Call-and-Live-Webcast-4170365  

wir tafeln in der Regel generell allwöchentlich werktags 9:00-20:00Uhr jegliche Daten auf,die für Ihr Interesse sind,Gruss Buran  

Nasdaq 21,55  $ -0,18% 21,59 $ 300 925.542 21,45 -  21,78 19:25:13  

Tradegate,weiss nicht vielleicht kommen die da in Kiel bei Ariva wieder mal nicht hinterher beim Einmeisseln,egal im Depot stehen die aber bereits und zwar in meinem ,ha ;-)))
kopier das nur nicht hier rein,denn das ist ja schliesslich Privat-Reinraum-Buran-Staions-Persönichlichkeit-Zwispalt-Geldtran­sver-Sphäre,gelle ;-)